Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

NCT03942224 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Plasma Cell Myeloma

Interventions

DRUG: Bortezomib
BIOLOGICAL: Daratumumab
DRUG: Dexamethasone
DRUG: Ixazomib

Sponsor

Emory University

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]